Thermal Stability of Bimatoprost, Latanoprost, and Travoprost Under Simulated Daily Use

Johnson, Thomas V.; Gupta, Preeya K.; Vudathala, Daljit; Blair, Ian A.; Tanna, Angelo P.

doi:10.1089/jop.2010.0115

Cited by 24 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other researchers have obtained similar measurements with commercial latanoprost (e.g. 57.7 ± 3.2 µg/mL) [20]. Latanoprost acid was detected in both release media and commercial latanoprost (0.037 ± 0.008 µg/mL and 1.03 µg/mL, respectively), but at concentrations that were far below those of latanoprost.…”

Section: Resultssupporting

confidence: 69%

In vivo performance of a drug-eluting contact lens to treat glaucoma for a month

Ciolino¹,

Ştefănescu²,

Ross³

et al. 2014

Biomaterials

165

122

View full text Add to dashboard Cite

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery, but achieving controlled drug release has been a significant challenge. We have developed a drug-eluting contact lens designed for prolonged delivery of latanoprost for the treatment of glaucoma, the leading cause of irreversible blindness worldwide. Latanoprost-eluting contact lenses were created by encapsulating latanoprost–poly(lactic-co-glycolic acid) films in methafilcon by ultraviolet light polymerization. In vitro and in vivo studies showed an early burst of drug release followed by sustained release for one month. Contact lenses containing thicker drug–polymer films demonstrated released a greater amount of drug after the initial burst. In vivo, single contact lenses were able to achieve, for at least one month, latanoprost concentrations in the aqueous humor that were comparable to those achieved with topical latanoprost solution, the current first-line treatment for glaucoma. The lenses appeared safe in cell culture and animal studies. This contact lens design can potentially be used as a treatment for glaucoma and as a platform for other ocular drug delivery applications.

show abstract

Section: Resultssupporting

confidence: 69%

In vivo performance of a drug-eluting contact lens to treat glaucoma for a month

Ciolino¹,

Ştefănescu²,

Ross³

et al. 2014

Biomaterials

165

122

View full text Add to dashboard Cite

show abstract

“…Several prostaglandin derivatives, including latanoprost, are reportedly susceptible to oxidation reactions, degraded into several oxidative products . Therefore, in order to decrease the contact of the labile derivative with the oxygen molecule, several kinds of oils and/or surfactants were employed, and the stabilizing effects were evaluated under stress conditions.…”

Section: Resultsmentioning

confidence: 79%

Effect of Oily Ingredients and Solid Adsorbents on the Chemical Stability of a Solid Dosage Form of Lubiprostone

Kim

Won

et al. 2019

Bulletin Korean Chem Soc

View full text Add to dashboard Cite

Lubiprostone (LPT), a novel laxative, is commercially available as a soft gelatin capsule with oily ingredient, complementing its poor water‐solubility and oxygen‐labile property. In the present study, in order to address drawbacks associated with soft capsule formulations such as difficulty in process control or high production costs, conversion of the drug‐loaded oil solution into powder dosage form was attempted using several oily ingredients and porous solid carriers. Drug solubilization in medium chain triglycerides (MCT) drastically improved the drug stability compared to that in powder or other oily ingredients, exhibiting over 95% of the drug remaining after 5 days of storage at 60 °C. However, conversion of drug‐loaded MCT into a free‐flowing powder using porous carriers markedly deteriorated drug stability. Although the drug stability in the solidified formulations prepared using Avicel PH 102 or Aerosil 200 were relatively higher than those prepared using metallic adsorbents (Florite, DCP A/T, and Neusilin US2), they were less stable than in the intact oil solution under stress and accelerated condition. This implied that the decreased thickness of the oily barrier in the solidified formula failed to inhibit the exposure of the labile compound to oxygen and/or moisture, thereby accelerating drug degradation. In vitro drug release from the adsorbent progressed rapidly, providing complete drug release within 15 min, under sink condition. This study suggests that the kind of oily vehicle and the thickness of the barrier are important factors for ensuring the stability of LPT, an oxygen‐labile compound, and additional pharmaceutical approaches are required for the construction of stable solid preparations.

show abstract

“…In a study done by Johnson et al, 12 to determine the concentration of bimatoprost, latanoprost, and travo-prost in conditions of simulated daily use and varying degree of thermal stress, medication bottles were stored in calibrated nonhumified, light-free incubators maintained at temperatures below and above the labeled indications for upto 30 days. They concluded that under all combinations of stress “off the shelf” bottles of these prostaglandin analogs showed mean bimatoprost concentration was 102% (100-116%) of the labeled concentration as compared to latanoprost which was 97 to 120% of the labeled concentration and travoprost was 83 to 143% of the labeled concentration.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations

Wadhwani

Mishra

Angmo

et al. 2016

Journal of Current Glaucoma Practice

View full text Add to dashboard Cite

Purpose: Comparative evaluation of pharmaceutical characteristics of three marketed generic vs branded travoprost formulations.Materials and methods: Three generic travoprost formulations and one branded (Travatan without benzalkonium chloride) formulation (10 vials each), obtained from authorized agents from the respective companies and having the same batch number, were used. These formulations were coded and labels were removed. At a standardized room temperature of 25°C, the drop size, pH, relative viscosity, and total drops per vial were determined for Travatan (Alcon, Fort Worth, TX, USA) and all the generic formulations. Travoprost concentration in all four brands was estimated by using liquid chromatography-coupled tandem mass spectrometry LCMS.Results: Out of the four formulations, two drugs (TP 1 and TP 4) were found to follow the United States Pharmacopoeia (USP) limits for ophthalmic formulation regarding drug concentration, while the remaining two drugs failed due to the limits being either above 110% (TP 2) or below 90% (TP 3). Two of them (TP 1 and TP 2) had osmolality of 313 and 262 mOsm respectively, which did not comply with the osmolality limits within 300 mOsm (+ 10%). The pH of all the formulations ranged between 4.7 and 5.9, and the mean drop size was 30.23 ± 6.03 uL. The total amount of drug volume in the bottles varied from 2.58 ± 0.15 to 3.38 ± 0.06 mL/bottle.Conclusion: There are wide variations in the physical properties of generic formulations available in India. Although some generic drugs are compliant with the pharmacopeia standards, this study underscores the need for a better quality control in the production of generic travoprost formulations.How to cite this article: Wadhwani M, Mishra SK, Angmo D, Velpandian T, Sihota R, Kotnala A, Bhartiya S, Dada T. Evaluation of Physical Properties of Generic and Branded Travoprost Formulations. J Curr Glaucoma Pract. 2016;10(2):49-55.

show abstract

Thermal Stability of Bimatoprost, Latanoprost, and Travoprost Under Simulated Daily Use

Cited by 24 publications

References 32 publications

In vivo performance of a drug-eluting contact lens to treat glaucoma for a month

In vivo performance of a drug-eluting contact lens to treat glaucoma for a month

Effect of Oily Ingredients and Solid Adsorbents on the Chemical Stability of a Solid Dosage Form of Lubiprostone

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations

Contact Info

Product

Resources

About